drugset / Trial / NCT06148948

A Study in Healthy Men to Test How Well Different Doses of BI 1584862 Are Tolerated

NCT06148948

Phase 1 Completed 32 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The goal of this trial is to investigate safety, tolerability and pharmacokinetics of BI 1584862 in healthy male subjects of Japanese ethnicity following oral administration of single rising doses.

Timeline

Start
2023-12-25
Primary completion
2024-05-21
Completion
2024-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1584862 Unknown Oral

Indications

No indication recorded.